TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00002833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: For GVHD prophylaxis, cyclosporine via continuous IV infusion. Oral cyclosporine administered once tolerating oral feeding and continued for 6 months postinfusion. Then dose tapered 10% weekly until discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (Ara-C)
Description: Group 1A: Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3; Group 1B: Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (Ara-C)
Description: Group 1A: Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3; Group 1B: Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: IV over 30 minutes daily on days -6, -5, -4 and -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: IV Days -6, -5 and -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: IV Days -6, -5 and -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Begins 5 days after infusion and is gradually tapered.
Study: NCT02808585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB1046 Injection
Description: Four weekly subcutaneous injections of PB1046.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB1046 Injection
Description: Four weekly subcutaneous injections of PB1046.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB1046 Injection
Description: Four weekly subcutaneous injections of PB1046.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: Four weekly subcutaneous injections of placebo.
Study: NCT01353170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysate calcium concentration
Description: Calcium dialysate concentrations: 1.25, 1.35 and 1.5 mmol/l
Study: NCT01903798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Immunosuppressive agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Corticosteroid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Corticosteroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Corticosteroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Corticosteroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilonacept
Study: NCT03143348

Intervention type: PROCEDURE
Intervention: Single blood draw
Description: One blood draw of 0.5 ml volume prior to discharge

Intervention type: PROCEDURE
Intervention: Multiple blood draws
Description: Blood draw at 6 peri-operative time points.

Intervention type: PROCEDURE
Intervention: Multiple blood draws
Description: Blood draw at 7 peri-operative time points
Study: NCT02712801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Dose will be adjusted according to the child's weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Dose will be adjusted according to the child's weight.
Study: NCT00791141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Loading dose prior to chemoradiotherapy 400 mg/m², followed by every week infusion of 250 mg/m² during chemoradiotherapy. After chemoradiotherapy every 2 week infusions of 500 mg/m² over 6 months.
Study: NCT00107042

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombivax
Description: Participants receive doses of Recombivax at weeks 0 and 24.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Twinrix
Description: Participants receive doses of Twinrix at weeks 0 and 24.
Study: NCT04317599

Intervention type: OTHER
Intervention: Non Interventional study
Description: Non Interventional study
Study: NCT01602471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]RDG-K5
Description: Approximately fifteen (15) patients with carotid artery stenosis \> 69% will undergo an endarterectomy and will be imaged under PET/CT with \[F-18\]RGD-K5
Study: NCT00957619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pentoxyfilline
Description: The total dose of 1 mg/kg/h will be used. At the preoperative day half of the daily dose will be given as a 4-hour short-term infusion within 24 hours before surgery. Afterwards, a continuous intravenous infusion of PTX 1 mg/kg of body weight per hour will be started intra-operatively and will be continued for a total of 72 hours after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will be treated with saline solution at the same time points. The infusion volume and infusion rate of saline solution correspond to that of the PTF group.
Study: NCT00761449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Initial dose is oral lenalidomide 10 mg daily continuously. The dose should be increased to 20 mg day 1 in week 6 and to 30 mg day 1 in week 10. This dose should be kept for seven weeks. Thus, the total study period is 16 weeks.
Study: NCT04015180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eylea (Aflibercept, BAY86-5321)
Description: Treatment administered in 20090. Solution in a sterile glass vial, Dose A, IVT injection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser photocoagulation
Description: Treatment administered in 20090. Transpupillary conventional laser ablative therapy
Study: NCT04821388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rontis DCB
Description: The Rontis DCB is intended for use as a percutaneous transluminal angioplasty (PTA) catheter to dilate stenotic or obstructive vascular lesions in the lower extremities for the purpose of improving limb perfusion and decreasing the incidence of restenosis.~In this study, it is intended to use Rontis DCB for treatment of lesions in the femoropopliteal arteries
Study: NCT03399617

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient Powders
Description: Micronutrient powders (5 nutrient formulation) are currently provided by the Guatemalan Ministry of Health to children between 6-24 months of age.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micronutrient Powders
Description: Micronutrient powders (5 nutrient formulation) are currently provided by the Guatemalan Ministry of Health to children between 6-24 months of age.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPOON behavioral change strategy
Description: An innovative behavioral change strategy designed using ethnographic and marketing methods to promote adequate infant and young child feeding practices and the use of SQ-LNS. The strategy will be delivered to mothers or caregivers through individual home-visits, group sessions, and community mobilization activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPOON behavioral change strategy
Description: An innovative behavioral change strategy designed using ethnographic and marketing methods to promote adequate infant and young child feeding practices and the use of SQ-LNS. The strategy will be delivered to mothers or caregivers through individual home-visits, group sessions, and community mobilization activities.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SQ-LNS
Description: SQ-LNS is a peanut-based ready to use home fortification product to improve diet quality in children 6-24 months of age. It includes peanuts and other ingredients such as vegetable fat, powdered milk and several micronutrients. The formulation designed for this study does not include sugar.
Study: NCT01949714

Intervention type: PROCEDURE
Intervention: Removal of adrenal tumor
Study: NCT00002833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Begins 5 days after infusion and is gradually tapered.
Study: NCT00911755

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endotracheal Intubation
Description: This study is comparing 2 currently accepted methods of endotracheal intubation: laryngoscopy and videolaryngoscopy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endotracheal Intubation
Study: NCT01226251

Intervention type: DEVICE
Intervention: In vitro chair side test
Description: Colour evaluation of a strip
Study: NCT01872702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: malaria elimination using DP and low-dose primaquine
Description: Treatment of all persons resident in the intervention villages including those who do not have malaria parasites as detected by rapid diagnostic test. This is to interrupt p.f malaria transmission by removing the reservoir of all potentially infectious people from the area.
Study: NCT00002829

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa
Description: Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Infused intravenously over 2 hours daily on Day -7 and -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Administered intravenously on Day -8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Beginning 1 hour after initiation of the cyclophosphamide treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Transplantation
Description: Infusion on Day 0.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Total body irradiation is received on days -4, -3, -2 , and -1.
Study: NCT01643226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riboflavin solution
Description: 0.12% riboflavin ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo solution
Description: 0.0% riboflavin ophthalmic solution

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: KXL System
Description: 30 mW/cm2
Study: NCT03617978

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodynamics parameters
Description: real-time evaluation of cardiac output parameters using the ICON device
Study: NCT03007147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV
Study: NCT03617978

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodynamics parameters
Description: real-time evaluation of cardiac output parameters using the ICON device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodynamics parameters
Description: real-time evaluation of cardiac output parameters using the ICON device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodynamics parameters
Description: real-time evaluation of cardiac output parameters using the ICON device
Study: NCT03943459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: Quercetin 250 mg BID
Study: NCT00002833

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Cell infusion Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Cell infusion Day 0.
Study: NCT04217889

Intervention type: OTHER
Intervention: Questionnaire
Description: Short questionnaire that can be completed during the usual consultation.
Study: NCT03007147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO
Study: NCT03635398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sipnose device
Description: SipNose's intranasal drug delivery platform uses an innovative mechanism that is suposed to improves efficacy, patient compliance and safety
Study: NCT03007147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO
Study: NCT03635398

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MAD (Mucosal Atomization Device)
Description: MAD (Mucosal Atomization Device)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: oral administration of midazolam
Study: NCT03007147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO or IV
Study: NCT02139943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Description: Canagliflozin capsule of 100 mg dose will be taken orally, before the first meal of the day.
Study: NCT02278289

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: Patients in the ultrasound therapy group were treated with US therapy for 5 minutes each session, twice per week for 8 weeks.
Study: NCT03007147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO
Study: NCT02278289

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paraffin therapy
Description: Patients in the paraffin therapy group were treated with the dip-and-wrap method of paraffin bath therapy in the hospital twice per week for 8 weeks. The temperature of the paraffin bath was maintained at approximately 55°C
Study: NCT03447613

Intervention type: PROCEDURE
Intervention: surgery
Description: All participants were scheduled to have elective total hip or knee replacement surgery, ureteroscopic lithotripsy and transurethral resection of the prostate under spinal anesthesia at the Shanghai 10th People's Hospital. After 5 years, the investigaors will follow up the participants including cognitive functions, PET-CT, thickness of Retinal Nerve Fiber Layer.
Study: NCT03007147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT
Study: NCT04751903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: oral motor stimulation
Description: Oral motor stimulation (OMS) is defined as the sensorial stimulation of cheek, lip, jaw, upper-lower gum, internal cheek, tongue and soft palate that affects the physiology of oropharyngeal mechanisms and develops feeding functions.It took 15 minutes to apply the OMS by lightly touching their cheeks, lips, gums, and tongue with fingertips for the first 12 minutes, followed by letting the infant suck on a pacifier for the remaining 3 minutes. OMS used as an alternative or supplementary early intervention strategy to develop oral feeding skills in preterm infants.
Study: NCT04096352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct Method
Description: Learning effective vocal skills using speech therapy exercises and virtual reality simulations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Indirect Method
Description: Information on voice function and voice hygiene.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indirect Method
Description: Information on voice function and voice hygiene.
Study: NCT03007147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT
Study: NCT02139943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Description: Canagliflozin capsule of 300 mg dose will be taken orally, before the first meal of the day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule will be taken orally, before the first meal of the day.
Study: NCT01097473

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Exercise training in outpatient sport groups once weekly with a duration of 60 min each
Study: NCT00077376

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study: NCT04120597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zishen Qingre Lishi Huayu Granules
Description: The treatment group used Zishen Qingre Lishi Huayu Granules, including Zhimu（Anemarrhena asphodeloides Bge.）, Shengdi（Rehmannia glutinosa Libosch.）, Maidong（Ophio pogon japonicus (L.f) KerGawl.） , Bixie（Dioscorea septemloma Thunb.）, Huanglian（Coptis chinensis Franch.）, Zhuling（Polyporus umbellatus（Pers.）Fries）, Xuanshen（Scrophularia ningpoensis Hemsl.）, Zelan（Lycopus lucidus Turcz. Var. Hirtus Regel）, Danshen（Salvia miltiorrhiza Beg.）， Gancao（Glycyrrhiza uralensis Fisch.）. Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment group used Caramel pigment、 Ku Ding Cha Extracts、Maltodextrin、Starch and 5% Zishen Qingre Lishi Huayu Granules .~Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months.
Study: NCT00077376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study: NCT02113072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone
Description: The wheezing infants will be using the inhaled corticosteroid beclomethasone 50mcg - 02 jets per day (100mcg/dia).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone
Description: The wheezing infants will be using the inhaled corticosteroid beclomethasone 50mcg - 02 jets per day (100mcg/dia).
Study: NCT00077376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study: NCT02113072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Lyophilized form, each sachet containing 1 g of the probiotic, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo will be supplied in the same way with the same organoleptic characteristics of formula with probiotics, 1 g sachet for 60 days, in the juice, milk or yoghurt.
Study: NCT03007147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV
Study: NCT00077376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04724382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally tailored healthy eating advice
Description: Culturally-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard healthy eating advice
Description: Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips for general dietary recommendations
Study: NCT03921255

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Bias Modification
Description: There is support that CBM-I may work through the process of cognitive restructuring, and specifically, threat reappraisal. Threat appraisal is a tendency to overestimate the likelihood of harm (i.e., likelihood bias) and/or the negative consequences of anticipated harm (i.e., Clark \& Beck, 2010), producing avoidance, thus interfering with effectively reappraising threat, thereby creating a vicious cycle (Beck et al., 1985; Clark \& Beck, 2010). CBM-I procedures ensure that an interpretation bias is triggered by the ambiguous scenarios, and participants are then guided to solve the key word in accordance with a healthy response (Grey \& Mathews, 2000). The observed effects of CBM-I may stem from active generation of benign or positive meanings in response to ambiguous situations, where threats were previously interpreted (Beadel et al., 2014).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Bias Modification
Description: There is support that CBM-I may work through the process of cognitive restructuring, and specifically, threat reappraisal. Threat appraisal is a tendency to overestimate the likelihood of harm (i.e., likelihood bias) and/or the negative consequences of anticipated harm (i.e., Clark \& Beck, 2010), producing avoidance, thus interfering with effectively reappraising threat, thereby creating a vicious cycle (Beck et al., 1985; Clark \& Beck, 2010). CBM-I procedures ensure that an interpretation bias is triggered by the ambiguous scenarios, and participants are then guided to solve the key word in accordance with a healthy response (Grey \& Mathews, 2000). The observed effects of CBM-I may stem from active generation of benign or positive meanings in response to ambiguous situations, where threats were previously interpreted (Beadel et al., 2014).
Study: NCT03007147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies